Benjamin Chaigne1, Axel Finckh2, Deshire Alpizar-Rodriguez2, Delphine Courvoisier2, Camillo Ribi3, Carlo Chizzolini4. 1. Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. 2. Rheumatology, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland. 3. Division of Immunology and Allergy, University Hospital, Lausanne, Switzerland. 4. Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. carlo.chizzolini@unige.ch.
Abstract
PURPOSE: This study examined and compared health-related quality of life (QoL) in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). METHODS: We included patients from two multicentric cohorts, the Swiss SLE cohort study (SSCS) and the Swiss Clinical Quality Management Program for RA (SCQM-RA). Patients were matched by age, sex and disease duration using the propensity score. Disease activity was assessed by SELENA-SLEDAI in SLE and by DAS-28 in RA. QoL was captured by the short-form 36 (SF-36). The primary outcomes were physical component summary (PCS) and mental component summary (MCS) of the SF-36. Generalized estimating equation models were used to assess evolution over time. RESULTS: We analyzed 267 SLE patients and 267 matched RA patients. More patients with RA had active disease and more patients with SLE had immunosuppressant therapies at baseline. The median [interquartile range (IQR)] MCS and PCS scores were 45.1 [33.7-52.6] and 45.6 [38.0-53.0] in SLE and 48.8 [37.6-56.7] and 34.7 [26.8-43.0] in RA, respectively (ps < 0.001). Over one year the differences persisted, although PCS and MCS increased in RA (ps < 0.001) but not in SLE in the univariate analysis. The differences in MCS and PCS scores between RA and SLE remained qualitatively similar after adjustment for patient characteristics, treatment, and activity disease. CONCLUSIONS: SLE and RA both affect QoL. Patients with SLE have lower MCS, whereas patients with RA have lower PCS. These differences remained over 1 year of follow up, suggesting fundamental dissimilarities between SLE and RA in their impact on QoL.
PURPOSE: This study examined and compared health-related quality of life (QoL) in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). METHODS: We included patients from two multicentric cohorts, the Swiss SLE cohort study (SSCS) and the Swiss Clinical Quality Management Program for RA (SCQM-RA). Patients were matched by age, sex and disease duration using the propensity score. Disease activity was assessed by SELENA-SLEDAI in SLE and by DAS-28 in RA. QoL was captured by the short-form 36 (SF-36). The primary outcomes were physical component summary (PCS) and mental component summary (MCS) of the SF-36. Generalized estimating equation models were used to assess evolution over time. RESULTS: We analyzed 267 SLEpatients and 267 matched RApatients. More patients with RA had active disease and more patients with SLE had immunosuppressant therapies at baseline. The median [interquartile range (IQR)] MCS and PCS scores were 45.1 [33.7-52.6] and 45.6 [38.0-53.0] in SLE and 48.8 [37.6-56.7] and 34.7 [26.8-43.0] in RA, respectively (ps < 0.001). Over one year the differences persisted, although PCS and MCS increased in RA (ps < 0.001) but not in SLE in the univariate analysis. The differences in MCS and PCS scores between RA and SLE remained qualitatively similar after adjustment for patient characteristics, treatment, and activity disease. CONCLUSIONS:SLE and RA both affect QoL. Patients with SLE have lower MCS, whereas patients with RA have lower PCS. These differences remained over 1 year of follow up, suggesting fundamental dissimilarities between SLE and RA in their impact on QoL.
Authors: Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi Journal: Arthritis Care Res (Hoboken) Date: 2012-05 Impact factor: 4.794
Authors: C Tani; D D'Aniello; A Delle Sedie; L Carli; M Cagnoni; N Possemato; M Carbone; A Della Rossa; L Riente; C Baldini; R Talarico; D Caramella; S Bombardieri; M Mosca Journal: Autoimmun Rev Date: 2012-10-11 Impact factor: 9.754
Authors: Chee-Seng Yee; Vernon T Farewell; David A Isenberg; Bridget Griffiths; Lee-Suan Teh; Ian N Bruce; Yasmeen Ahmad; Anisur Rahman; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; Christopher Edwards; David D'Cruz; Munther A Khamashta; Caroline Gordon Journal: Rheumatology (Oxford) Date: 2011-01-18 Impact factor: 7.580
Authors: Elena Elefante; Chiara Tani; Chiara Stagnaro; Francesco Ferro; Alice Parma; Linda Carli; Viola Signorini; Dina Zucchi; Umberto Peta; Adele Santoni; Leonardo Raffaelli; Marta Mosca Journal: RMD Open Date: 2020-02
Authors: Elena Elefante; Chiara Tani; Chiara Stagnaro; Viola Signorini; Alice Parma; Linda Carli; Dina Zucchi; Francesco Ferro; Marta Mosca Journal: Arthritis Res Ther Date: 2020-10-14 Impact factor: 5.156